Every S-1 that Eloxx Pharmaceuticals, Inc. (ELOX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ELOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELOX filings page.
Eloxx Pharmaceuticals, Inc. (ELOX) has filed a Form S-1 registering a resale offering for selling stockholders of 600,000 shares of common stock plus up to 4,358,919 additional shares issuable upon exercise of outstanding pre-funded warrants. Eloxx is not selling any shares in this registration.
The pre-funded warrants were issued in prior private placements, carry a cash exercise price of $0.11 per share, are exercisable at any time and remain outstanding until fully exercised, subject to a beneficial ownership limitation. Eloxx will receive no proceeds from stockholder resales, but would receive about $0.5 million if all pre-funded warrants are exercised for cash. As of June 30, 2026, 4,036,398 shares of common stock were outstanding, and the stock traded at $16.28 per share on Nasdaq on September 10, 2026.
Eloxx is a clinical-stage biopharmaceutical company focused on ribosome-modulating small molecules targeting nonsense mutations, led by exaluren for rare kidney diseases, with additional programs in autosomal dominant polycystic kidney disease and a partnered asset, ZKN-013, licensed to Almirall. The company reports an accumulated deficit of $308.8 million, continued operating losses, prior Nasdaq delisting and filing delinquencies, and states its existing cash and cash equivalents are expected to fund current and planned operations at least twelve months from this prospectus date and currently to mid-2028.
Eloxx Pharmaceuticals is conducting a primary offering of 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 additional shares. The assumed public offering price is between $10.00 and $12.00 per share or pre-funded warrant, with each warrant exercisable for one share at $0.01.
The company’s common stock currently trades on the OTC Pink market under “ELOX”, and completion of this offering is contingent on approval for listing on the Nasdaq Capital Market. Eloxx is a clinical-stage biopharmaceutical company focused on exaluren for rare kidney diseases and a licensed program, ZKN-013, for rare skin diseases. It has incurred recurring losses, an accumulated deficit of $304.3 million as of March 31, 2026, cash and cash equivalents of $6.4 million and a going concern warning, though pro forma cash after the offering would rise to $60.6 million with positive working capital.
Eloxx Pharmaceuticals is registering 1,500,000 shares of common stock and pre-funded warrants to purchase up to 4,000,000 additional shares in a primary offering, with the shares underlying the pre-funded warrants also covered. The company plans to price common shares between $10.00 and $12.00 and will adjust the mix of shares and pre-funded warrants on a one-for-one basis at pricing.
Eloxx’s common stock currently trades on the OTC Pink market under “ELOX,” and the closing of this offering is contingent on approval to list on the Nasdaq Capital Market. The company is a clinical-stage biopharmaceutical developer of ribosome-modulating therapies, led by its exaluren program for Alport syndrome with nonsense mutations and a preclinical program in autosomal dominant polycystic kidney disease.
Eloxx has a history of losses and limited capital, with 2025 revenue of $6.4 million from licensing, a 2025 net loss of $6.0 million, and a further $3.8 million net loss in the three months ended March 31, 2026. As of March 31, 2026, it reported $6.4 million in cash and cash equivalents, a $7.6 million stockholders’ deficit, and its auditors and management cited substantial doubt about its ability to continue as a going concern without new financing, including proceeds from this offering.
Eloxx Pharmaceuticals, Inc. is seeking to raise capital through a public offering of common stock and pre-funded warrants, with the closing contingent on securing a listing of its common stock on the Nasdaq Capital Market under the symbol “ELOX”. The company is currently quoted on the OTC Expert Market and was previously delisted from Nasdaq after failing to meet market value requirements and becoming delinquent in SEC filings.
Eloxx is a clinical-stage biopharmaceutical company focused on exaluren, a ribosome-modulating small molecule being developed for Alport syndrome with nonsense mutations and autosomal dominant polycystic kidney disease, and on ZKN-013, which is licensed to Almirall for rare skin diseases. The company reported a net loss of $6.0 million in 2025 and $3.8 million for the three months ended March 31, 2026, had $6.4 million in cash and cash equivalents and an accumulated deficit of $304.3 million, and its auditors expressed substantial doubt about its ability to continue as a going concern.